You are here

  • Home
  • Archive
  • Volume 74, Issue 2
  • Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status

Article info

Article menu
Download PDFPDF
Original research
Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status

Authors

  • Mikaela Holmes Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Annabelle Mahar Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Trina Lum Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Steven Kao Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, New South Wales, Australia Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  • Wendy Anne Cooper Department of Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia School of Medicine, Western Sydney University, Sydney, New South Wales, Australia PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Wendy Anne Cooper, Tissue Pathology and Diagnostic Oncology, NSW Health Pathology, Royal Prince Alfred Hospital, Camperdown NSW 2050, New South Wales, Australia; wendy.cooper{at}health.nsw.gov.au
View Full Text

Citation

Holmes M, Mahar A, Lum T, et al
Real-world programmed death-ligand 1 prevalence rates in non-small cell lung cancer: correlation with clinicopathological features and tumour mutation status
Journal of Clinical Pathology 2021;74:123-128.

Publication history

  • Received April 30, 2020
  • Revised May 28, 2020
  • Accepted May 29, 2020
  • First published June 23, 2020.
Online issue publication 
January 27, 2021

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.